Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Navigating Low-Grade Serous Ovarian Cancer – Enhancing Diagnosis, Sequencing Therapy, and Contextualizing Novel Advances
View More
Burst CME™: Implementing Appropriate Recognition and Diagnosis of Low-Grade Serous Ovarian Cancer
View More
Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials
View More
Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care
View More
Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care
View More
Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!
Survivor Volunteer Program Provides Support for Newly Diagnosed Patients
August 1st 2001BALTIMORE-Women undergoing breast cancer treatment at the Johns Hopkins Breast Center receive extensive emotional support from breast cancer survivor volunteers, thanks to an ongoing program there. Lillie Shockney, RN, MAS, director of education and outreach, described the development and implementation of the program at a poster session at the Oncology Nursing Society’s 26th Annual Congress.
No Survival Advantage for High-Dose vs Standard Chemotherapy
August 1st 2001SAN FRANCISCO-High-dose chemotherapy plus stem cell rescue did not improve overall survival vs standard chemotherapy alone in women with chemotherapy-sensitive metastatic breast cancer, according to the results of a National Cancer Institute of Canada (NCIC) trial reported at the 37th Annual Meeting of the American Society of Clinical Oncology (ASCO).
Prophylactic Mastectomy Effective in Mutation Carriers
August 1st 2001ROTTERDAM, The Netherlands-In the first prospective study of its kind, prophylactic mastectomy prevented the development of breast cancer in women at high risk for breast cancer because of BRCA1/2 mutations, compared with controls who did not opt for surgery.
FIRE Project Shows Walking Program Decreases Fatigue in Breast Cancer Patients
August 1st 2001BALTIMORE-What is safe, efficacious, and cost-effective, not swallowed or taken intravenously, and improves a breast cancer patient’s quality of life? Exercise, according to a group of researchers who conducted a multi-institutional, prospective, randomized controlled trial examining the effects of a supervised walking regimen on breast cancer patients.
Docetaxel Regimen Better Tolerated Than Doxorubicin in Adjuvant Breast Cancer Setting
August 1st 2001SAN FRANCISCO-Results are now emerging regarding the use of docetaxel (Taxotere) in the adjuvant breast cancer setting. A large study presented at the 37th Annual Meeting of the American Society of Clinical Oncology (ASCO) evaluated the adjuvant use of docetaxel plus cyclophosphamide (TC 75/600 mg/m²) and found it to be better tolerated than standard doxorubicin (Adriamycin) plus cyclophosphamide (AC 60/600 mg/m²).
High- vs Intermediate-Dose Chemotherapy in Stage II/IIIa Breast Cancer
August 1st 2001SAN FRANCISCO-Cancer and Leukemia Group B (CALGB) 9082 has failed in its second analysis to show a survival benefit for intensive therapy and transplant in primary breast cancer patients with multiple positive axillary lymph nodes. Nevertheless, outcomes in the 785-patient study, which compared high-dose and intermediate-dose consolidation chemotherapy with alkylating agents, are superior to outcomes achieved in studies of standard-dose therapy alone, William P. Peters, MD, PhD, said on behalf of investigators in the study, which was started more than 10 years ago. Dr. Peters, director of the Karmanos Cancer Institute, Detroit, spoke at the 37th Annual Meeting of the American Society of Clinical Oncology (ASCO).
Double Reading Mammograms Increases Cancer Detection Rate, Costs
August 1st 2001SEATTLE-Double reading mammograms increases breast cancer detection rates but not without substantial costs, according to a study done at Fletcher Allen Health Care, Burlington, Vermont, and presented at the 101st Annual Meeting of the American Roentgen Ray Society.
Current Clinical Trials of the Anti-VEGF Monoclonal Antibody Bevacizumab
August 1st 2001Given the well-established role of angiogenesis (or new blood vessel formation) in tumor growth and metastasis, antiangiogenic therapy, a concept first proposed by Dr. Judah Folkman,[1] has become increasingly recognized as a promising
Commentary (Harvey): Nonsteroidal and Steroidal Aromatase Inhibitors in Breast Cancer
August 1st 2001Anastrozole (Arimidex), letrozole (Femara), and exemestane (Aromasin) are members of the third generation of aromatase inhibitors that has now replaced aminoglutethimide (Cytadren), the progestins, and tamoxifen
Commentary (Buzdar): Nonsteroidal and Steroidal Aromatase Inhibitors in Breast Cancer
August 1st 2001Anastrozole (Arimidex), letrozole (Femara), and exemestane (Aromasin) are members of the third generation of aromatase inhibitors that has now replaced aminoglutethimide (Cytadren), the progestins, and tamoxifen
Neoadjuvant Weekly Paclitaxel Ups Breast Cancer Pathologic Complete Response Rates
July 1st 2001SAN FRANCISCO-Preliminary results of an ongoing phase III study suggest that weekly paclitaxel (Taxol) followed by FAC (fluorouracil/Adriamycin/cyclophosphamide) provides improved pathologic complete response rates, compared with standard paclitaxel followed by FAC, M.D. Anderson researchers reported at the 37th Annual Meeting of the American Society of Clinical Oncology (ASCO), held in San Francisco.
Decision Board Helps Breast Cancer Patients Assess Chemotherapy Options, Increases Satisfaction
July 1st 2001SAN FRANCISCO-Canadian breast cancer patients who tested a decision aid called the Decision Board in a randomized trial were better informed about their chemotherapy options and more satisfied with the decision-making process than a control group of patients who relied on a traditional medical consultation.
Over 20% of Breast Cancer Patients Risk Recurrence by Not Taking Their Tamoxifen
July 1st 2001SAN FRANCISCO-One in five women in a population-based study of breast cancer patients did not fill all her tamoxifen (Nolvadex) prescriptions during the first year of adjuvant tamoxifen therapy. The oldest and youngest patients and nonwhite patients were least likely to adhere to their tamoxifen regimens.
Can Cognitive Dysfunction in Breast Cancer Patients Be Prevented?
July 1st 2001DALLAS-Responding to a growing body of research that suggests cognitive dysfunction and asthenia are prevalent side effects of adjuvant chemotherapy for breast cancer, Joyce O’Shaughnessy, MD, of US Oncology is investigating recombinant human erythropoietin as a neuroprotective agent.
Estrogen Replacement Therapy Does Not Increase Breast Cancer Recurrence
July 1st 2001WASHINGTON-Fear that hormones may increase the risk of cancer recurrence has long discouraged US physicians from recommending estrogen replacement therapy (ERT) to breast cancer survivors, despite its proven advantages for health and quality of life.
Physician Recalls Breast Cancer Battle at the South Pole
July 1st 2001NEW YORK-"I’m going to die," Jerri Nielsen, MD, recalled thinking when she discovered a lump in her right breast while she was the physician at the Admundsen-Scott South Pole Station. "I’m going to die here, or I’m going to die after I get off the ice."
Breast Cancer Survivors Are at High Risk for Osteoporosis
July 1st 2001PONTE VEDRA BEACH, Fla-Eighty percent of breast cancer survivors were found to have osteoporosis or osteopenia at the outset of a University of Nebraska Medical Center College of Nursing pilot study into preventing osteoporosis among survivors.
Docetaxel Plus Doxorubicin Ups Response in Metastatic Breast Cancer
July 1st 2001SAN FRANCISCO-The addition of docetaxel (Taxotere) to an anthracycline (doxorubicin)-containing regimen may improve response rates in the first-line treatment of metastatic breast cancer. The findings come from a large international trial, TAX 307, presented at the 37th Annual Meeting of the American Society of Clinical Oncology (ASCO) in San Francisco.
NCI Accelerating Molecular Diagnosis and Therapy for Breast Cancer
July 1st 2001WASHINGTON-Cutting-edge molecular research supported by the National Cancer Institute (NCI) promises revolutionary changes in the way physicians screen, diagnose, and treat breast cancer, NCI director Richard D. Klausner, MD, told the Senate appropriations subcommittee that oversees the NCI.
Elderly Breast Cancer Survivors Receive More Preventive Care Services
July 1st 2001SAN FRANCISCO-Elderly women who survived breast cancer received more preventive health care overall than a matched control group of cancer-free women. This finding was based on a review of financial records by researchers at the Center for Outcomes and Policy Research at Dana-Farber Cancer Institute in Boston.
Treatment-Induced Amenorrhea Remains Controversial in Premenopausal Breast Cancer
July 1st 2001SAN FRANCISCO-The impact of achieving amenorrhea during treatment for premenopausal breast cancer is controversial, according to data from the National Cancer Institute of Canada (NCIC) Clinical Trials Group (CTG). A common occurrence among premenopausal breast cancer patients, treatment-induced amenorrhea is often considered a positive prognostic factor. The NCIC CTG data was unable to demonstrate such an effect.
Weekly Epoetin Alfa Boosts Energy and Activity Levels
July 1st 2001SAN FRANCISCO-Anemic breast cancer patients receiving chemoradiotherapy who are also treated with weekly recombinant human erythropoietin (epoetin alfa [Procrit, Eprex, Erypo]) have not only better hemoglobin levels but also improved energy, activity levels, and overall quality of life.